Nautilus Biotechnology, Inc. Accrued Liabilities, Current
Nautilus Biotechnology, Inc. (NAUT) had Accrued Liabilities, Current of $1.65 million as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:AccruedLiabilitiesCurrent · last filed 2021-05-13
- 2021-03-31: Accrued Liabilities, Current $1.65M.
- 2020-12-31: Accrued Liabilities, Current $388.51K.
- 2020-09-30: Accrued Liabilities, Current $102.57K.
- 2020-06-30: Accrued Liabilities, Current $125.00K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2021-03-31 | $1.65M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $388.51K 10-Q · filed 2021-05-13 |
| 2020-09-30 | $102.57K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $125.00K 10-Q · filed 2020-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |